Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11.25
Benzinga Newsdesk 22 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $11 to $11.25.
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $11 to $11.25.
